Packer S, Coderre J, Saraf S, Fairchild R, Hansrote J, Perry H
Department of Ophthalmology, North Shore University Hospital-Cornell University Medical College, Manhasset, New York.
Invest Ophthalmol Vis Sci. 1992 Feb;33(2):395-403.
Boron neutron capture therapy (BNCT) is a form of radiation therapy that requires selective uptake of boron by the tumor and irradiation with thermal neutrons. Phenylalanine is an amino acid precursor of melanin and when boronated (p-boronophenylalanine [BPA]) was found to be selectively taken up by Greene melanoma cells in the anterior chamber of rabbits. This tumor model was irradiated 24 hr after oral administration of BPA and was used for biodistribution studies that compared BPA and sodium pentaborate. Three groups were irradiated: group 1 (11 rabbits) received BPA followed by thermal neutron irradiation, group 2 (9 rabbits) received thermal neutron irradiation only, and group 3 (9 rabbits) served as unirradiated, undrugged control animals. Eight of the 11 tumors in group 1 were treated successfully; all tumors in groups 2 and 3 grew. Histopathologic examination did not reveal vascular or retina damage in group 1. These preliminary experiments confirm that newer boronated compounds, such as BPA, used in BNCT and improved neutron beams can provide selective irradiation of ocular melanomas.
硼中子俘获疗法（BNCT）是一种放射治疗形式，它要求肿瘤选择性摄取硼并接受热中子照射。苯丙氨酸是黑色素的一种氨基酸前体，当硼化后（对硼苯丙氨酸[BPA]），发现其能被兔前房中的格林氏黑色素瘤细胞选择性摄取。在口服BPA 24小时后，对该肿瘤模型进行照射，并用于比较BPA和五硼酸钠的生物分布研究。共对三组进行照射：第1组（11只兔子）接受BPA后进行热中子照射，第2组（9只兔子）仅接受热中子照射，第3组（9只兔子）作为未照射、未用药的对照动物。第1组的11个肿瘤中有8个成功得到治疗；第2组和第3组的所有肿瘤均生长。组织病理学检查未发现第1组有血管或视网膜损伤。这些初步实验证实，BNCT中使用的新型硼化化合物，如BPA，以及改进的中子束能够对眼部黑色素瘤进行选择性照射。
